The Treatment of Gliomas in Adulthood.

BACKGROUND Gliomas are the most common intrinsic tumors of the brain, with an incidence of 6 per 100 000 persons per year. Recent years have seen marked changes in the diagnosis and treatment of gliomas, with molecular parameters now being an integral part of the diagnostic evaluation. METHODS This review is based on pertinent articles retrieved by a selective search in PubMed, with special attention to the new WHO glioma classification. RESULTS The classification of gliomas on the basis of additional molecular parameters enables more accurate prognostication and serves as a basis for therapeutic decision-making and treatment according to precisely specified algorithms. PET scanning with 18F-fluoroethyl tyrosine and 11C-methionine for the measurement of metabolic activity in gliomas has further refined the diagnostic evaluation. The median overall survival of patients with glioblastoma who have undergone resection of all tumor tissue with a disrupted blood-brain barrier (i.e., all contrast-enhancing tumor tissue) has been prolonged to up to 20 months. The 5-year survival of patients with WHO grade II gliomas is now as high as 97% after near-total resection. The surgical resection of all contrast-enhancing tumor tissue and subsequent radiotherapy and chemotherapy remain the key elements of treatment. New surgical strategies and new methods of planning radiotherapy have made these techniques safer and more effective. The percutaneous application of tumor-treating fields is a new therapeutic option that has gained a degree of acceptance. Accompanying measures such as psycho-oncology and palliative care are very important for patients and should be considered mandatory. CONCLUSION The consistent application of the existing multimodal treatment options for glioma has led in recent years to improved survival. Areas of important current and future scientific activity include immunotherapy and targeted and combined chemotherapy, as well as altered neurocognition, modern approaches to palliative care, and complementary therapies.

[1]  F. Lieberman,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.

[2]  D. Brachman,et al.  Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study , 2017, The Lancet.

[3]  Act Investigators Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .

[4]  M. Ruge,et al.  Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression. , 2017, World neurosurgery.

[5]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[6]  M. Weller,et al.  European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. , 2017, The Lancet. Oncology.

[7]  M. Ruge,et al.  Impact of treatment on survival of patients with secondary glioblastoma , 2017, Journal of Neuro-Oncology.

[8]  F. Berthold,et al.  Feasibility, Risk Profile and Diagnostic Yield of Stereotactic Biopsy in Children and Young Adults with Brain Lesions , 2017, Klinische Pädiatrie.

[9]  Nadim Jon Shah,et al.  Advances in neuro-oncology imaging , 2017, Nature Reviews Neurology.

[10]  D. Osoba,et al.  Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma , 2017, The New England journal of medicine.

[11]  A. Grosu,et al.  Re-irradiation for Recurrent Primary Brain Tumors. , 2016, Anticancer research.

[12]  Brigitta G. Baumert,et al.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma , 2016, The Lancet. Oncology.

[13]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[14]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[15]  Walter J. Curran,et al.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. , 2016, The New England journal of medicine.

[16]  Thomas C. Chen,et al.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. , 2015, JAMA.

[17]  Steven N. Kalkanis,et al.  The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. , 2015 .

[18]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[19]  E. Chiocca,et al.  How much is enough? The question of extent of resection in glioblastoma multiforme. , 2014, World neurosurgery.

[20]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[21]  C. Vecht,et al.  Seizure characteristics and prognostic factors of gliomas , 2013, Epilepsia.

[22]  Christian Grefkes,et al.  Mapping the hand, foot and face representations in the primary motor cortex — Retest reliability of neuronavigated TMS versus functional MRI , 2013, NeuroImage.

[23]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Herzog,et al.  Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis , 2012, The Journal of Nuclear Medicine.

[26]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[27]  G. Fink,et al.  Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI , 2012, The Journal of Nuclear Medicine.

[28]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[29]  Damien C Weber,et al.  Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  Frank Berthold,et al.  Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[32]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Gabriele Schackert,et al.  Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. , 2008, Neuro-oncology.

[35]  E. Shaw,et al.  Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. , 2008, Journal of neurosurgery.

[36]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[38]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[39]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[40]  M. Ruge,et al.  Impact of resection on survival of IDH 1-mut WHO II astrocytoma after malignant progression , 2017 .

[41]  L. Recht,et al.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. , 2017, The Lancet. Oncology.

[42]  Claus Belka,et al.  ESTRO-ACROP guideline "target delineation of glioblastomas". , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  B. Meyer,et al.  Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. , 2016, Neuro-oncology.

[44]  K. Langen,et al.  [Use of amino acid PET in the Diagnostic and Treatment Management of cerebral gliomas]. , 2012, Fortschritte der Neurologie-Psychiatrie.

[45]  I. Tannock,et al.  Placebo effects in oncology. , 2003, Journal of the National Cancer Institute.

[46]  A. Muacevic,et al.  The Risk of Haemorrhage after Image Guided Stereotactic Biopsy of Intra-Axial Brain Tumours – A Prospective Study , 2001, Acta Neurochirurgica.